Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of mTOR inhibitors for treatment of sarcomas.

Literature DB >> 17588357

The role of mTOR inhibitors for treatment of sarcomas.

Abstract

Bone and soft tissue sarcomas represent rare tumors that can be cured by local treatment at early stages of disease. However, advanced or metastatic disease is rarely cured, and very few drugs have shown efficacy in this setting. Early studies with mTOR inhibitors have demonstrated antitumor activity in patients with metastatic sarcoma who failed previous chemotherapies. The response rate and durable stable disease in early studies, as well as the tolerability profile, recommend these drugs as promising candidates for further clinical studies. This article discusses preliminary results from clinical trials in patients with advanced or metastatic sarcoma as well as future perspectives.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2007 PMID： 17588357 DOI： 10.1007/s11912-007-0039-7

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

28 in total

1. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.

Authors: D A Fruman; M A Wood; C K Gjertson; H R Katz; S J Burakoff; B E Bierer
Journal: Eur J Immunol Date: 1995-02 Impact factor: 5.532

2. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors: Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544

Review 3. Current development of mTOR inhibitors as anticancer agents.

Authors: Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal: Nat Rev Drug Discov Date: 2006-08 Impact factor: 84.694

4. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

Authors: H B Jefferies; S Fumagalli; P B Dennis; C Reinhard; R B Pearson; G Thomas
Journal: EMBO J Date: 1997-06-16 Impact factor: 11.598

5. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors: M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205

6. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors: Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal: J Clin Oncol Date: 2006-09-05 Impact factor: 44.544

7. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Authors: A Sekulić; C C Hudson; J L Homme; P Yin; D M Otterness; L M Karnitz; R T Abraham
Journal: Cancer Res Date: 2000-07-01 Impact factor: 12.701

8. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors: P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal: Nat Genet Date: 1997-04 Impact factor: 38.330

9. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Authors: Eric Raymond; Jérôme Alexandre; Sandrine Faivre; Karina Vera; Eric Materman; Joseph Boni; Cathie Leister; Joan Korth-Bradley; Axel Hanauske; Jean-Pierre Armand
Journal: J Clin Oncol Date: 2004-05-10 Impact factor: 44.544

Review 10. Predicted mechanisms of resistance to mTOR inhibitors.

Authors: R T Kurmasheva; S Huang; P J Houghton
Journal: Br J Cancer Date: 2006-09-05 Impact factor: 7.640

15 in total

1. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

Authors: Scott Okuno; Howard Bailey; Michelle R Mahoney; Douglas Adkins; William Maples; Tom Fitch; David Ettinger; Charles Erlichman; Jann N Sarkaria
Journal: Cancer Date: 2011-02-01 Impact factor: 6.860

2. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Authors: Swati Sikaria; Josefine Heim-Hall; Elizabeth H Diaz; Ronald Williams; Kamelesh Sankhala; Brenda Laabs; Monica Mita
Journal: Target Oncol Date: 2013-02-21 Impact factor: 4.493

The role of mTOR inhibitors for treatment of sarcomas.

1. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.

2. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Review 3. Current development of mTOR inhibitors as anticancer agents.

4. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

5. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

6. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

7. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

8. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

9. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Review 10. Predicted mechanisms of resistance to mTOR inhibitors.

1. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

2. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Review 3. Soft tissue sarcomas with complex genomic profiles.

Review 4. Molecular classification of soft tissue sarcomas and its clinical applications.

5. The kinase Mirk is a potential therapeutic target in osteosarcoma.

Review 6. Novel targets with potential therapeutic applications in osteosarcoma.

7. Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.

8. The role of mirk kinase in sarcomas.

9. The combination of rapamycin and MAPK inhibitors enhances the growth inhibitory effect on Nara-H cells.

Review 10. Molecular mechanisms underpinning sarcomas and implications for current and future therapy.